SMR

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx ®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Valu

October 9, 2024

8

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx ®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Valu

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced…